Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selvigaltin - Galecto Biotech

Next Previous
X
Search
Drug Profile

Selvigaltin - Galecto Biotech

Alternative Names: GB-1211

Latest Information Update: 23 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galecto Biotech
  • Developer Galecto Biotech; Galecto Inc; Roche
  • Class 1 ring heterocyclic compounds; Antifibrotics; Antineoplastics; Fluorobenzenes; Hepatoprotectants; Pyridines; Small molecules; Sulfides; Triazoles
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma; Squamous cell cancer
  • Phase I/II Liver cirrhosis; Non-small cell lung cancer
  • Phase I Hepatic fibrosis
  • No development reported Non-alcoholic steatohepatitis; Pulmonary fibrosis

Most Recent Events

  • 27 Mar 2024 Pharmacokinetics and adverse event data from phase I trials in Hepatic fibrosis presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2024)
  • 29 Feb 2024 Phase-II clinical trials in Malignant melanoma (Metastatic disease, Late-stage disease, Inoperable/Unresectable, Recurrent, Combination therapy) in USA (PO) (NCT05913388)
  • 29 Feb 2024 Phase-II clinical trials in Squamous cell cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable, Recurrent, Combination therapy) in USA (PO) (NCT05913388)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top